	US 12,263,154 B2
	Composition using 4′,6,7-trimethoxyisoflavone and catechol for managing pulmonary fibrosis
Moon Jae Cho, Jeju-do (KR); Young Mee Kim, Jeju-do (KR); and Bong Jo Son, Jeju-do (KR)
Assigned to A-CHEMBIO CO., LTD, Gyeonggi-do (KR)
Appl. No. 17/612,712
Filed by A-CHEMBIO CO., LTD, Gyeonggi-do (KR)
PCT Filed Jul. 6, 2021, PCT No. PCT/KR2021/008552 § 371(c)(1), (2) Date Nov. 19, 2021, PCT Pub. No. WO2022/010219, PCT Pub. Date Jan. 13, 2022.
Claims priority of application No. 10-2020-0084225 (KR), filed on Jul. 8, 2020.
Prior Publication US 2022/0218655 A1, Jul. 14, 2022
Int. Cl. A61K 31/352 (2006.01); A61K 31/05 (2006.01); A61P 11/00 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 31/05 (2013.01); A61P 11/00 (2018.01)]

3 Claims

1. A method for managing pulmonary fibrosis, comprising

administering to a subject in need thereof a composition comprising a mixture of 4′,6,7-trimethoxyisoflavone and catechol as an active ingredient.